HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that clinical results from the Company’s studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the South Central American Urological Association Meeting in Colorado Springs this weekend on September 8. The paper is authored by leading clinical research investigators from U.S. clinical trials of NX-1207.
